# Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

> **NCT03342859** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 10 (actual)

## Conditions studied

- Leiomyoma

## Interventions

- **DRUG:** Vilaprisan, BAY1002670
- **DRUG:** Ulipristal

## Key facts

- **NCT ID:** NCT03342859
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-16
- **Primary completion:** 2018-12-17
- **Final completion:** 2020-01-13
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Due to findings in the preclinical carcinogenicity studies for vilaprisan (BAY1002670)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03342859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03342859, "Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03342859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*